ETx-22, a Novel Nectin-4-Directed Antibody-Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4-Expressing Tumors

Cancer Res Commun. 2024 Nov 1;4(11):2998-3012. doi: 10.1158/2767-9764.CRC-24-0176.

Abstract

ETx-22, a novel ADC combining a tumor nectin-4-specific antibody and an innovative linker to exatecan, demonstrates significant and durable responses in low-target-expressing tumor models that are resistant to MMAE-based EV and has a better toxicity profile. This new ADC has the potential to benefit additional patient populations beyond its current indication.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Cell Adhesion Molecules* / antagonists & inhibitors
  • Cell Adhesion Molecules* / immunology
  • Cell Adhesion Molecules* / metabolism
  • Cell Line, Tumor
  • Female
  • Humans
  • Immunoconjugates* / pharmacology
  • Immunoconjugates* / therapeutic use
  • Mice
  • Nectins
  • Neoplasms / drug therapy
  • Neoplasms / immunology
  • Xenograft Model Antitumor Assays

Substances

  • Immunoconjugates
  • NECTIN4 protein, human
  • Cell Adhesion Molecules
  • Antineoplastic Agents
  • Nectins